Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Press release

Transgene Announces Upcoming Investor Meetings

20190829 PR financial Agenda

Published 29 August 2019
Categorized as 2019, Press release

Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer

20190807 – Transgene Update EN

Published 7 August 2019
Categorized as 2019, Pexa-Vec, Press release

Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis

20190802 PHOCUS Interim Analysis US

Published 2 August 2019
Categorized as 2019, Pexa-Vec, Press release

Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases

20190718 – TRANSGENE PR MHRA TG6002

Published 18 July 2019
Categorized as 2019, Press release, TG6002

Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK

20190710 PR MHRA TG4050 EN

Published 10 July 2019
Categorized as 2019, Myvac, Press release, TG4050

Success of Transgene’s €48.7 Million Rights Issue

http://finance.transgene.fr/en/launch.php

Published 2 July 2019
Categorized as 2019, Press release

Transgene Announces the Launch of a Rights Issue

http://finance.transgene.fr/en/launch.php

Published 14 June 2019
Categorized as 2019, Press release

Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002

20190605 Transgene publi TG4001 TG6002 EN

Published 5 June 2019
Categorized as 2019, Press release, TG4001, TG6002

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

20190527-PR-Last-patient-TG4010-1L-EN

Published 27 May 2019
Categorized as 2019, Press release, TG4010

Combined General Meeting of May 22, 2019

20190522-TG-AGM-2019-EN

Published 22 May 2019
Categorized as 2019, Press release

Posts pagination

Newer posts Page 1 … Page 21 … Page 33 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu